Mixture of inorganic compounds, preparations containing the mixture and use of the mixture
AssigneeSea QIQ AS
InventorsRune Eritzland, Harald Molnes
Life of this patent
Estimating the term…
Abstract
A mineral mixture including at least' MgO and its equilibrium of Mg(OH)2, and MgCl2, in which MgO—Mg(OH)2 constitutes between 85 and 99.99% by weight; and MgCl2 constitutes between 0.01 and 15% by weight of the magnesium compounds in the mineral mixture. Preparations containing the salt mixture and the use of the mineral mixture for the production of a pharmaceutical preparation for the prevention or therapy of a condition, the condition being undesired eczema or psoriasis, are also described.
Claims18
A mineral mixture, the mineral mixture comprising:
- MgO;
- an amount of Mg(OH)2 that establishes an equilibrium with the MgO;
- and
- MgCl2 wherein a total amount of the MgO and the Mg(OH)2 constitutes between 85% and 99.99% by weight of the mineral mixture and further wherein the MgCl2 constitutes between 0.01% and 15% by weight of the mineral mixture.
A mineral mixture, the mineral mixture comprising:
- MgO;
- an amount of Mg(OH)2that establishes an equilibrium with the MgO;
- MgCl2 wherein a total amount of the MgO and the Mg(OH)2 constitutes between 63% and 80% by weight of the mineral mixture and further wherein the MgCl2 constitutes between 0.01% and 11% by weight of the mineral mixture;
- NaCl that constitutes between 15% and 31% by weight of the mineral mixture;
- and
- a group of other minerals that constitutes between 0% and 7% by weight of the mineral mixture wherein the group of other minerals is formed by SiO2, CaSO4, NaBr and MgBr2.
A preparation containing a mineral mixture having magnesium compounds, wherein the preparation comprises:
- MgO;
- an amount of Mg(OH)2 that establishes an equilibrium with the MgO;
- and
- MgCl2 wherein a total amount of the MgO and the Mg(OH)2 constitutes between 85% and 99.99% by weight of the mineral mixture and further wherein the MgCl2 constitutes between 0.01% and 15% by weight of the mineral mixture.
A method for producing a pharmaceutical preparation using a mineral mixture for the prevention and therapy of a skin disease wherein the skin disease is selected from the group consisting of undesired eczema and undesired psoriasis, the method comprising the steps of:
- forming the mineral mixture with MgO, an amount of Mg(OH)2 that establishes an equilibrium with the MgO and MgCl2 wherein a total amount of the MgO and the Mg(OH)2 constitutes between 85% and 99.99% by weight of the mineral mixture and further wherein the MgCl2 constitutes between 0.01% and 15% by weight of the mineral mixture;
- and
- combining the mineral mixture with a pharmaceutically acceptable carrier for treating the skin disease.
A preparation containing a mineral mixture having magnesium compounds, wherein the preparation comprises:
- MgO;
- an amount of Mg(OH)2 that establishes an equilibrium with the MgO;
- MgCl2 wherein a total amount of the MgO and the Mg(OH)2 constitutes between 63% and 80% by weight of the mineral mixture and further wherein the MgCl2 constitutes between 0.01% and 11% by weight of the mineral mixture;
- NaCl that constitutes between 15% and 31% by weight of the mineral mixture;
- and
- a group of other minerals that constitutes between 0% and 7% by weight of the mineral mixture wherein the group of other minerals is formed by SiO2, CaSO4, NaBr and MgBr2.
A method for producing a pharmaceutical preparation using a mineral mixture for the prevention and therapy of a skin disease wherein the skin disease is selected from the group consisting of undesired eczema and undesired psoriasis, the method comprising the steps of:
- forming the mineral mixture with MgO, an amount of Mg(OH)2 that establishes an equilibrium with the MgO, MgCl2, NaCL and a group of other minerals wherein a total amount of the MgO and the Mg(OH)2 constitutes between 63% and 80% by weight of the mineral mixture wherein the MgCl2 constitutes between 0.01% and 11% by weight of the mineral mixture wherein the NaCl constitutes between 15% and 31% by weight of the mineral mixture and further wherein the group of other minerals constitutes between 0% and 7% by weight of the mineral mixture wherein the group of other minerals is formed by SiO2, CaSO4, NaBr and MgBr2;
- and
- combining the mineral mixture with a pharmaceutically acceptable carrier for treating the skin disease.
Dependencies are inferred from the claim text.